JP5118796B2 - 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法 - Google Patents

二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法 Download PDF

Info

Publication number
JP5118796B2
JP5118796B2 JP2001506824A JP2001506824A JP5118796B2 JP 5118796 B2 JP5118796 B2 JP 5118796B2 JP 2001506824 A JP2001506824 A JP 2001506824A JP 2001506824 A JP2001506824 A JP 2001506824A JP 5118796 B2 JP5118796 B2 JP 5118796B2
Authority
JP
Japan
Prior art keywords
apo
ligand
formulation
zinc
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001506824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003503057A (ja
Inventor
アシュケナジ，アヴィ，ジェー．
ハイモヴィッツ，サラ
ロバート， エフ． ケリー，
コーメニス，インフィゲニア
ルング，スーザン
オコーネル，マーク
パイ，ロジャー
シャロカ，ザーラ
シモンズ，ローラ
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2003503057A publication Critical patent/JP2003503057A/ja
Application granted granted Critical
Publication of JP5118796B2 publication Critical patent/JP5118796B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2001506824A 1999-06-28 2000-06-26 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法 Expired - Lifetime JP5118796B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14134299P 1999-06-28 1999-06-28
US60/141,342 1999-06-28
PCT/US2000/017579 WO2001000832A1 (en) 1999-06-28 2000-06-26 Methods for making apo-2 ligand using divalent metal ions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010253233A Division JP2011088897A (ja) 1999-06-28 2010-11-11 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法

Publications (2)

Publication Number Publication Date
JP2003503057A JP2003503057A (ja) 2003-01-28
JP5118796B2 true JP5118796B2 (ja) 2013-01-16

Family

ID=22495287

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001506824A Expired - Lifetime JP5118796B2 (ja) 1999-06-28 2000-06-26 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
JP2010253233A Pending JP2011088897A (ja) 1999-06-28 2010-11-11 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010253233A Pending JP2011088897A (ja) 1999-06-28 2010-11-11 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法

Country Status (12)

Country Link
US (3) US7855066B1 (enExample)
EP (3) EP2311956A1 (enExample)
JP (2) JP5118796B2 (enExample)
KR (1) KR100674528B1 (enExample)
CN (2) CN100526463C (enExample)
AU (3) AU6338200A (enExample)
CA (1) CA2377585A1 (enExample)
ES (1) ES2392392T3 (enExample)
IL (2) IL147029A0 (enExample)
MX (1) MXPA01013236A (enExample)
NZ (2) NZ537920A (enExample)
WO (1) WO2001000832A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
EP1873244A3 (en) * 1999-06-02 2008-04-02 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
IL147029A0 (en) * 1999-06-28 2002-08-14 Genentech Inc Method for making apo-2 ligand using divalent metal ions
JP2005508162A (ja) * 2001-10-02 2005-03-31 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド変異体とその使用法
AU2007200478A1 (en) * 2001-11-13 2007-02-22 Genentech, Inc. APO2 ligand/trail formulations
IL161812A0 (en) * 2001-11-13 2005-11-20 Genentech Inc Apo2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
EP1556076A4 (en) * 2002-06-24 2009-07-08 Genentech Inc APO-2 LIGAND / TRAIL VARIANTS AND ITS USES
GB0328261D0 (en) 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
SI1733037T1 (sl) 2004-03-11 2015-02-27 Genentech, Inc. Postopek za izdelavo polipeptidov
AU2005271601A1 (en) 2004-08-06 2006-02-16 Genentech, Inc. Assays and methods using biomarkers
MX2007001468A (es) 2004-08-06 2007-03-26 Genentech Inc Ensayos y metodos que utilizan biomarcadores.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
PT1915626E (pt) 2005-08-16 2012-02-03 Genentech Inc Sensibilidade da apoptose a apo2l/trail por ensaio de expressão de galnac-t14 em células/tecidos
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
CN102775491A (zh) * 2011-05-09 2012-11-14 中国人民解放军第二军医大学 单链化的人凋亡素2配体三聚体蛋白质的制法和用途
CN102443055B (zh) * 2011-10-26 2017-07-28 浙江海正药业股份有限公司 一种重组人肿瘤坏死因子相关凋亡诱导配体的纯化工艺
JP6355425B2 (ja) * 2014-05-20 2018-07-11 キヤノン株式会社 システムおよびその制御方法
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
EP3430034A1 (en) * 2016-03-16 2019-01-23 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
CN119461783A (zh) * 2019-04-04 2025-02-18 株式会社小原 光学玻璃的制造方法
JP7429622B2 (ja) * 2020-08-26 2024-02-08 株式会社オハラ 光学ガラスの製造方法
CN115980241B (zh) * 2023-02-11 2025-01-07 烟台新特路新材料科技有限公司 一种硫代酯类抗氧化剂含量的检测方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0257956B2 (en) 1986-08-19 2000-11-22 Genentech, Inc. Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion
JPH04501201A (ja) 1987-12-21 1992-03-05 ジ・アップジョン・カンパニー 発芽植物種子類のアグロバクテリウム媒介形質転換
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
CA2087267A1 (en) 1990-08-17 1992-02-18 Steven H. Bass Metal ion mediated receptor binding of polypeptide hormones
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1992017200A2 (en) 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations
US6387650B1 (en) * 1995-06-07 2002-05-14 Biocontrol Systems, Inc. Method and composition for detecting bacterial contamination in food products
KR100510234B1 (ko) * 1995-06-29 2005-11-25 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
DE19547933A1 (de) * 1995-12-22 1997-06-26 Boehringer Mannheim Gmbh Multimere Formen von IL-16, Verfahren zu ihrer Herstellung und Verwendung
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
CA2256464A1 (en) 1996-06-07 1997-12-11 Amgen Inc. Tumor necrosis factor-related polypeptide
AU733380B2 (en) 1996-10-03 2001-05-10 Regents Of The University Of Michigan, The Nucleotide and protein sequence of mammastatin and methods of use
EP0939804B2 (en) 1996-10-25 2011-06-15 Human Genome Sciences, Inc. NEUTROKINE alpha
DE951551T1 (de) 1996-12-23 2000-09-14 Immunex Corp., Seattle Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
RO128635A2 (ro) 1997-04-16 2013-07-30 Amgen Inc. Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp
ATE516354T1 (de) 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
ES2331900T3 (es) 1997-08-26 2010-01-19 Genentech, Inc. Receptor rtd.
ES2316182T3 (es) * 1998-01-15 2009-04-01 Genentech, Inc. Ligando apo-2.
SE9802454D0 (sv) 1998-07-08 1998-07-08 Pharmacia & Upjohn Ab Production of peptides
IL147029A0 (en) * 1999-06-28 2002-08-14 Genentech Inc Method for making apo-2 ligand using divalent metal ions
AU6891800A (en) 1999-09-10 2001-04-10 Eli Lilly And Company Flint analog compounds and formulations thereof
WO2001018041A2 (en) 1999-09-10 2001-03-15 Eli Lilly And Company Flint proteins and formulations thereof
JP2005508162A (ja) * 2001-10-02 2005-03-31 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド変異体とその使用法
IL161812A0 (en) * 2001-11-13 2005-11-20 Genentech Inc Apo2 ligand/trail formulations
CN100500841C (zh) * 2005-10-10 2009-06-17 华东理工大学 一种表达可溶性trail蛋白的方法

Also Published As

Publication number Publication date
CN1370232A (zh) 2002-09-18
KR20020016856A (ko) 2002-03-06
JP2003503057A (ja) 2003-01-28
US20070161564A1 (en) 2007-07-12
MXPA01013236A (es) 2002-06-21
JP2011088897A (ja) 2011-05-06
WO2001000832A1 (en) 2001-01-04
EP2339003A3 (en) 2011-10-19
IL147029A0 (en) 2002-08-14
AU6338200A (en) 2001-01-31
IL147029A (en) 2012-02-29
NZ537920A (en) 2006-10-27
ES2392392T3 (es) 2012-12-10
NZ515990A (en) 2003-10-31
KR100674528B1 (ko) 2007-01-29
EP1194555A1 (en) 2002-04-10
AU2005211561A1 (en) 2005-10-13
EP2339003A2 (en) 2011-06-29
CA2377585A1 (en) 2001-01-04
WO2001000832A9 (en) 2012-03-08
CN100526463C (zh) 2009-08-12
EP1194555B1 (en) 2012-09-26
AU2005211561B2 (en) 2008-08-21
US7855066B1 (en) 2010-12-21
US20120077740A1 (en) 2012-03-29
CN101633692A (zh) 2010-01-27
EP2311956A1 (en) 2011-04-20
AU2008249162A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
JP5118796B2 (ja) 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
JP4603023B2 (ja) Ａｐｏ−２リガンド変異体とその使用法
JP4574350B2 (ja) Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
JP2007530008A (ja) Ａｐｏ−２ｌレセプター結合ペプチド及びその使用
RU2435781C2 (ru) Способ очистки аро-2 ligand/trail посредством кристаллизации на холоде
AU2011265480A1 (en) Methods for making APO-2 ligand using divalent metal ions
HK1140780A (en) Methods for making apo-2 ligand using divalent metal ions
AU2007201621A1 (en) Apo-2 ligand variants and uses thereof
AU2002330173A1 (en) Apo-2 ligand variants and uses thereof
AU2011235952A1 (en) APO-2 ligand variants and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100811

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100910

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101012

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110928

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111027

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120925

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121022

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5118796

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151026

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term